🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06350305
Starting soon Observational

Screening for High-risk Chronic Obstructive Pulmonary Disease

NCT06350305 · tracked via the Priya Life Science China tracker
Sponsor
Henan University of Traditional Chinese Medicine
Phase
Observational
Started
2024-05-01
Last updated
2024-04-11

Condition(s) studied

High-risk COPD

Investigational drug(s) / intervention(s)

questionnaire survey

questionnaire survey: subjects fill out questionnaires

Study summary

This study is a multicenter cross-sectional study design aimed at screening risk factors for the combination of disease and syndrome in high-risk individuals with chronic obstructive pulmonary disease (COPD).

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * According to the Diagnosis and Treatment Guidelines for Chronic Obstructive Pulmonary Disease (Revised in 2021), a multi-stage cluster random sampling method was used to select individuals from representative administrative villages with a history of chronic cough or sputum production, breathing difficulties, recurrent lower respiratory tract infections, and/or exposure to potential risk factors for chronic obstructive pulmonary disease. * The investigators agreed to participate in this clinical study by voluntarily signing an informed consent form. Exclusion Criteria: * Patients who are delirious, have impaired consciousness, dementia, various psychiatric disorders, etc., and cannot be accurately informed of their basic physical condition. * Patients who, in the opinion of the investigator, are not suitable for participation in this study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The First Affiliated Hospital of Henan University of Chinese Medicine Zhengzhou Henan

More Henan University of Traditional Chinese Medicine trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06350305 on ClinicalTrials.gov ↗ ← All trials in China